Introduction {#tca12847-sec-0005}
============

Lung cancer is the leading cause of cancer death worldwide.[1](#tca12847-bib-0001){ref-type="ref"} Non‐small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases.[2](#tca12847-bib-0002){ref-type="ref"} For most clinical stage IIIb (American Joint Committee on Cancer, seventh edition \[AJCC 7E\]) NSCLC patients with good performance status, concurrent chemoradiotherapy (CCRT) is the standard of care,[3](#tca12847-bib-0003){ref-type="ref"}, [4](#tca12847-bib-0004){ref-type="ref"} and the addition of immunotherapy might improve progression‐free survival.[3](#tca12847-bib-0003){ref-type="ref"}, [5](#tca12847-bib-0005){ref-type="ref"}

However, for a specific NSCLC subpopulation with mutant *EGFR* (m*EGFR*, usually adenocarcinoma), the optimal treatment is less clear. For stage IV NSCLC with sensitizing m*EGFR*, upfront EGFR‐tyrosine kinase inhibitors (TKIs, such as gefitinib, erlotinib, afatinib, or osimertinib) are the current standard of care.[6](#tca12847-bib-0006){ref-type="ref"} However, a consensus paper in 2016 stated that there was "no data supporting the use of EGFR TKIs in patients with stage I--III disease,"[7](#tca12847-bib-0007){ref-type="ref"} although a recent randomized study reported improved disease‐free survival with adjuvant gefitinib after resection[8](#tca12847-bib-0008){ref-type="ref"} while another randomized phase II trial reported improved progression‐free survival (PFS) for TKI plus radiotherapy for unresected stage III disease compared to CCRT.[9](#tca12847-bib-0009){ref-type="ref"} In addition, AJCC 7E clinical stage IIIb NSCLC patients with m*EGFR* are eligible for TKI therapy in some modern trials.[10](#tca12847-bib-0010){ref-type="ref"}, [11](#tca12847-bib-0011){ref-type="ref"}

National Health Insurance (NHI) is a single‐payer, compulsory social insurance program that provides insurance coverage to almost all citizens in Taiwan.[12](#tca12847-bib-0012){ref-type="ref"} The benefit package is comprehensive (inpatient, outpatient, dental services, and even traditional Chinese medicine) and all medically necessary services are covered. Gefitinib has been reimbursed since June 2011 as first‐line treatment for stage IIIb--IV lung adenocarcinoma with m*EGFR*. Erlotinib and afatinib have also been reimbursed for the same indication since November 2013 and May 2014, respectively. Therefore, there is a unique opportunity to compare the effectiveness of TKIs in this population. The aim of our study was to compare TKIs versus CCRT for the treatment of AJCC 7E clinical stage IIIb lung adenocarcinoma with m*EGFR* (LA‐m*EGFR*) using population‐based data in Taiwan.

Methods {#tca12847-sec-0006}
=======

Data sources {#tca12847-sec-0007}
------------

The Health and Welfare Data Science Center, Ministry of Health and Welfare (HWDC) database provided complete information from the Taiwan Cancer Registry (TCR, until 2015), death registry (until 31 December 2016), and National Health Insurance (NHI) reimbursement data (until 31 December 2016) for the whole Taiwan population, provided by the Bureau of NHI.[13](#tca12847-bib-0013){ref-type="ref"} The quality of the TCR was verified in 2015.[14](#tca12847-bib-0014){ref-type="ref"} NHI data has been used in many population‐based studies. All data are compiled by the HWDC and de‐identified. The institutional review board approved this study (CMUH107‐REC3‐006).

Study design, setting, study population, and variables {#tca12847-sec-0008}
------------------------------------------------------

Unresected AJCC 7E clinical stage IIIb lung adenocarcinoma patients diagnosed between 2011/6 and 2015 with m*EGFR* and good Eastern Cooperative Oncology Group performance status (ECOG PS) 0--1, aged ≥ 18 were included in the study.[15](#tca12847-bib-0015){ref-type="ref"} Patients who underwent surgery as part of their treatment before disease progression, received palliative treatment, or had other cancer(s) within three years were excluded. Two treatment strategies were included for comparison: TKIs (gefitinib, erlotinib, or afatinib) and CCRT with platinum‐based chemotherapy and at least a 50 Gy radiotherapy dose (see Appendix [A](#tca12847-supitem-0001){ref-type="supplementary-material"} in supplementary data for the working definition). The threshold of 50 Gy was chosen based on a systemic review.[16](#tca12847-bib-0016){ref-type="ref"}

The study outcomes were overall survival (OS) and lung cancer‐specific survival (LCSS), as identified by the death registry. We also identified patient demographics (age, gender, and residency region), disease factors (subtypes of stage IIIb), patient characteristics (comorbidity and smoking history), and diagnostic approach (use of positron emission tomography \[PET\]) as potential confounders. These confounders were selected and modified as per our experience in clinical practice and TCR/NHI related studies, and were defined as follows.[17](#tca12847-bib-0017){ref-type="ref"}, [18](#tca12847-bib-0018){ref-type="ref"}, [19](#tca12847-bib-0019){ref-type="ref"}, [20](#tca12847-bib-0020){ref-type="ref"} Patient residency was classified as northern Taiwan or elsewhere. Stage was classified as T3--4/N3 versus others according to AJCC 8th edition (stage IIIc vs. IIIb). Smoking history was classified as yes or no. Comorbidity was defined as with or without a modified Carlson comorbidity score ≥ 1. Use of PET (time window: 2 months before to 4 months after diagnosis) was classified as yes or no.[21](#tca12847-bib-0021){ref-type="ref"}

Statistical methods and additional analyses {#tca12847-sec-0009}
-------------------------------------------

We used a log‐rank test and the Kaplan--Meier method for primary survival analyses. We then used the Cox regression model to include the potential confounders to reduce any bias. We calculated the E‐value in sensitivity analysis, as suggested by the literature, to evaluate the impact of potentially unmeasured confounder(s).[22](#tca12847-bib-0022){ref-type="ref"} We performed several additional analyses (AA). In the first and second AA, we used the propensity score (PS) method, as advocated in the literature, to balance the measured potential confounders to examine the robustness of our findings.[23](#tca12847-bib-0023){ref-type="ref"}, [24](#tca12847-bib-0024){ref-type="ref"} We used the covariables in the PS model via various methods (traditional logistic regression models, as well as machine learning, such as neural network \[NN\] or random forest \[RF\]) to estimate the possible PS value.[25](#tca12847-bib-0025){ref-type="ref"}, [26](#tca12847-bib-0026){ref-type="ref"}, [27](#tca12847-bib-0027){ref-type="ref"}, [28](#tca12847-bib-0028){ref-type="ref"} We then evaluated the covariate balance via standardized difference, as suggested by several review papers.[25](#tca12847-bib-0025){ref-type="ref"}, [29](#tca12847-bib-0029){ref-type="ref"}, [30](#tca12847-bib-0030){ref-type="ref"}, [31](#tca12847-bib-0031){ref-type="ref"} Finally, we used two methods: inverse probability weighting (IPW in the first AA) and PS matching (PSM, 1:1 paired matching in the second AA) to evaluate the effectiveness of TKI versus CCRT.[24](#tca12847-bib-0024){ref-type="ref"} In the 3rd--5th, AA we evaluated the impact of alternative study cohort definitions. In the third AA, we evaluated the impact of modifying patient age (\< 75), as patients at older age are suggested as being ineligible for CCRT.[32](#tca12847-bib-0032){ref-type="ref"} In the fourth AA, we evaluated the impact of modifying the working definition if a radiotherapy dose of at least 60 Gy was required.[3](#tca12847-bib-0003){ref-type="ref"} In the fifth AA, we evaluated the impact if TKIs were limited to gefitinib only. In addition to the five AA conducted, we also evaluated subsequent treatments in the groups. We used SAS 9.4 (SAS Institute Inc., Cary, NC, USA), STATA/IC 11 (Stata Corp, College Station, TX, USA), and R 3.5.0 (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria) to implement all analyses.

Results {#tca12847-sec-0010}
=======

Study population and descriptive data {#tca12847-sec-0011}
-------------------------------------

Our study flowchart, as suggested by the STROBE guideline, is depicted in Figure [1](#tca12847-fig-0001){ref-type="fig"}.[33](#tca12847-bib-0033){ref-type="ref"} In brief, 199 (TKI 177, CCRT 22) unresected clinical stage IIIb LA‐m*EGFR* patients with good ECOG PS were included in our study (Table [1](#tca12847-tbl-0001){ref-type="table"}). The TKI group were older, more likely to be female, living in south Taiwan, and at T3--4N3 stage and less likely to be smokers than the CCRT group, although the results were only statistically significant for age, residency region, and smoking.

![STROBE study flowchart and numbers of individuals at each stage of study. ^1^We only included those treated (class 1--2) at any single institution to ensure data consistency. ^2^Although patients with incomplete information were excluded from Step 4, 199 patients remained for Step 5.](TCA-9-1398-g002){#tca12847-fig-0001}

###### 

Characteristics of the study population in primary analysis

                                                     CCRT            TKI       
  --------------------------------------------- -------------- --------------- ----------
  Age                                            60.14 (7.78)   70.16 (10.90)   \< 0.001
  Gender                                                                       
  Female                                           12 (55)        110 (62)        0.49
  Male                                             10 (45)         67 (38)     
  Residency region                                                             
  Non‐north                                         3 (14)        107 (60)      \< 0.001
  North                                            19 (86)         70 (40)     
  Comorbidity                                                                  
  Without                                          10 (45)         75 (42)        0.78
  With[†](#tca12847-note-0002){ref-type="fn"}      12 (55)        102 (58)     
  Smoking history                                                              
  Without                                          11 (50)        131 (74)       0.019
  With                                             11 (50)         46 (26)     
  Sub‐types of stage IIIb                                                      
  T3--4N3                                           6 (27)         68 (38)        0.31
  Others                                           16 (73)        109 (62)     
  Use of PET                                                                   
  Without                                          11 (50)         89 (50)        0.98
  With                                             11 (50)         88 (50)     

Modified Carlson comorbidity score ≥ 1.

Rounded.

CCRT, concurrent chemoradiotherapy; PET, positron emission tomography; SD, standard deviation; TKI, tyrosine kinase inhibitor.

Outcome and results in primary analysis {#tca12847-sec-0012}
---------------------------------------

After a median follow‐up of 23 months (range: 1--64), 90 patients had died (80 in the TKI and 10 in the CCRT group). The Kaplan--Meier OS curve is shown in Figure [2](#tca12847-fig-0002){ref-type="fig"}. There were no statistically significant differences between the groups (log rank test *P* = 0.51\]. The three‐year OS rates for the TKI and CCRT groups were 55% and 60%, respectively. There was also no statistically significant difference after adjusting for potential confounders. The adjusted hazard ratio (HR) of death with a 95% confidence interval (CI) was 0.71 (0.34--1.47) for TKI versus CCRT (Table [2](#tca12847-tbl-0002){ref-type="table"}). The observed HR of 0.71 could be explained by an unmeasured confounder that was associated with both selections of treatment and life/death by a risk ratio of 1.85‐fold each (E‐value), but weaker confounding could not do so. The results for LCSS (HR 0.65, 95% CI 0.31--1.35) were not significant.

![Kaplan--Meier overall survival curve (in years) in primary analysis. (![](TCA-9-1398-g001.jpg "image")) CCRT, concurrent chemoradiotherapy, (![](TCA-9-1398-g003.jpg "image")) TKI, tyrosine kinase inhibitors.](TCA-9-1398-g004){#tca12847-fig-0002}

###### 

Survival analysis via Cox regression

  Characteristic                                 HR (95% CI)[‡](#tca12847-note-0006){ref-type="fn"}   *P* [‡](#tca12847-note-0006){ref-type="fn"}
  --------------------------------------------- ---------------------------------------------------- ---------------------------------------------
  Age                                                            1.03 (1.01--1.06)                                       0.009
  Gender                                                                                             
  Female (reference)                                                                                 
  Male                                                           1.12 (0.65--1.94)                                       0.68
  Residency region                                                                                   
  Non‐north (reference)                                                                              
  North                                                          0.73 (0.46--1.16)                                       0.18
  Comorbidity                                                                                        
  Without (reference)                                                                                
  With[†](#tca12847-note-0005){ref-type="fn"}                    1.01 (0.64--1.60)                                       0.96
  Smoking history                                                                                    
  Without (reference)                                                                                
  With                                                           0.73 (0.39--1.37)                                       0.33
  Treatment                                                                                          
  CCRT (reference)                                                                                   
  TKI                                                            0.71 (0.34--1.47)                                       0.36
  Subtypes of stage IIIb                                                                             
  T3--4N3 (reference)                                                                                
  Others                                                         0.51 (0.33--0.80)                                       0.003
  Use of PET                                                                                         
  Without (reference)                                                                                
  With                                                           0.73 (0.48--1.11)                                       0.14

Modified Carlson comorbidity score ≥ 1.

Rounded.

CCRT, concurrent chemoradiotherapy; CI, confidence interval; HR, hazard ratio; PET, positron emission tomography; TKI, tyrosine kinase inhibitor.

Additional analyses {#tca12847-sec-0013}
-------------------

In the first AA, two of the seven covariables were well balanced (i.e. standardized difference \[SDif\] ≤ 0.1) before IPW (Table [3](#tca12847-tbl-0003){ref-type="table"}).[29](#tca12847-bib-0029){ref-type="ref"}, [30](#tca12847-bib-0030){ref-type="ref"} The IPW via RF‐based PS could achieve a better (but still not optimal) covariable balance in that three covariables could be well‐balanced and five could be moderately balanced (i.e. SDif \< 0.25),[26](#tca12847-bib-0026){ref-type="ref"} whereas only one and five of the seven covariables could be well and moderately balanced, respectively, by LR‐based PS. Because RF but not NN achieved a better covariable balance, we only used RF to represent the results using machine learning in the following analyses. There was no statistically significant difference between TKI and CCRT, except when using RF approaches. The adjusted HR of death was 0.49 (95% CI 0.34--0.70; *P* \< 0.0001) for IPW via RF and 1.57 (95% CI 0.74--3.31; *P* = 0.24) for IPW via LR. In the second AA, the covariable balance was better (but still not optimal) in the LR‐based (*n* = 30) than the RF‐based PSM (*n* = 14) in that two and six of the seven covariables could be well and moderately balanced, respectively, by LR, whereas only three and four of the seven covariables could be well and moderately balanced by RF (Table [4](#tca12847-tbl-0004){ref-type="table"}). There was still no statistically significant difference between TKI and CCRT. The adjusted HR of death was 1.23 (95% CI 0.32--4.67; *P=* 0.77) for LR‐based and 0.27 (95% CI 0.03--2.45; *P* = 0.25) for RF‐based PSM.

###### 

Covariable balance diagnostics: Before and after IPW

                            Standardized difference[†](#tca12847-note-0008){ref-type="fn"}                  
  ------------------------ ---------------------------------------------------------------- ------- ------- -------
  Age                                                   1.059                                0.276   1.060   0.167
  Gender                                                0.155                                0.198   0.155   0.055
  Residency region                                      1.108                                0.106   1.109   0.381
  Comorbidity                                           0.062                                0.231   0.063   0.463
  Smoking history                                       0.511                                0.031   0.511   0.169
  Subtypes of stage IIIb                                0.239                                0.240   0.238   0.089
  Use of PET                                            0.006                                0.317   0.007   0.031

Rounded.

IPW, inverse probability weighting; LR, logistic regression; NN, neural network; PET, positron emission tomography; RF, random forest.

###### 

Characteristics of the matched study population in the second additional analyses

                                                 LR‐based PSM (*n* = 30)                   RF‐based PSM (*n* = 14)                                                                                      
  --------------------------------------------- ------------------------- --------------- ------------------------- ----------------------------------------- ----------------------------------------- -------
  Age                                                 62.93 (6.33)         60.47 (13.31)            0.237                         54.43 (7.81)                              55.86 (7.49)                 0.187
  Gender                                                                                                                                                                                                
  Female                                                 9 (60)               8 (53)                0.135            [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}   0.302
  Male                                                   6 (40)               7 (47)                                 [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}  
  Residency region                                                                                                                                                                                      
  Non‐north                                              3 (20)               4 (27)                0.158            [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}  
  North                                                  12 (80)              11 (73)                                [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}  
  Comorbidity                                                                                                                                                                                           
  Without                                                8 (53)               6 (40)                0.270                            3 (43)                                    3 (43)                      0
  With[†](#tca12847-note-0010){ref-type="fn"}            7 (47)               9 (60)                                                 4 (57)                                    4 (57)                   
  Smoking history                                                                                                                                                                                       
  Without                                                9 (60)               9 (60)                  0              [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}   0.354
  With                                                   6 (40)               6 (40)                                 [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}  
  Subtypes of stage IIIb                                                                                                                                                                                
  T3--4N3                                                6 (40)               6 (40)                  0              [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}     0
  others                                                 9 (60)               9 (60)                                 [§](#tca12847-note-0012){ref-type="fn"}   [§](#tca12847-note-0012){ref-type="fn"}  
  Use of PET                                                                                                                                                                                            
  Without                                                7 (47)               8 (53)                0.134                            4 (57)                                    4 (57)                      0
  With                                                   8 (53)               7 (47)                                                 3 (43)                                    3 (43)                   

Modified Carlson comorbidity score ≥ 1.

Rounded.

Exact numbers are not reported because the Health and Welfare Data Science Center database center policy is to avoid numbers in single cells ≤ 2.

CCRT, concurrent chemoradiotherapy; LR, logistic regression; PET, positron emission tomography; PSM, propensity‐score matching; RF, random forest; SD, standard deviation; TKI, tyrosine kinase inhibitor.

In the third AA, the result was robust to the modified age criteria (age \< 75) as the adjusted HR of death was not statistically different (1.03, 95% CI 0.47--2.29) for 111 TKI versus 21 CCRT patients. In the fourth AA, the result was also robust to the treatment criteria modification (at least 60 Gy instead of 50 Gy for CCRT) as the adjusted HR of death was not statistically different (HR 0.77, 95% CI 0.36--1.63) for 177 TKI versus 21 CCRT patients. In the fifth AA, our results were similar to the treatment criteria modification (including only gefitinib) as the adjusted HR of death was 0.83 (95% CI 0.39--1.76) for 112 TKI versus 22 CCRT patients.

Regarding subsequent treatment, 83 of 177 TKI patients received platinum‐based chemotherapy or radiotherapy, whereas most (as per HWDC policy, numbers ≤ 2 cannot be reported) of the 22 CCRT patients received TKIs. For the 10 patients diagnosed in 2011, almost all (as per HWDC policy, the exact number cannot be reported) patients in the TKI group received subsequent platinum‐based chemotherapy or radiotherapy, whereas all patients in the CCRT group received subsequent TKIs.

Discussion {#tca12847-sec-0014}
==========

In this population‐based study from Taiwan, the survival outcome of AJCC 7E clinical stage IIIb LA‐m*EGFR* patients was not statistically different between those treated with EGFR‐TKIs or CCRT. To our knowledge, this is the first study to compare the outcomes of these two treatments in LA‐m*EGFR* patients.

The most relevant study we located was a 2013 Japanese study in which the treatment strategies of 49 NSCLC patients with m*EGFR* and inoperable stage III/IV disease were compared. EGFR‐TKIs (*n* = 32) achieved tumor shrinkage earlier than radiotherapy (*n* = 17), although no statistically significant difference in PFS was found (295 for TKI vs. 273 days for RT).[34](#tca12847-bib-0034){ref-type="ref"} However, all TKI patients had stage IV disease, while 94% patients in the radiotherapy group (88% combined with chemotherapy) had stage III disease.

The results of our study are comparable with those published in the literature. In the CCRT group, our five‐year OS result was approximately 30% (at 4.88/year) (Fig [2](#tca12847-fig-0002){ref-type="fig"}). A phase III trial reported five‐year OS rates in stage III NSCLC patients treated with CCRT of 23% to 32% (for 74 Gy and 60 Gy, respectively).[35](#tca12847-bib-0035){ref-type="ref"}, [36](#tca12847-bib-0036){ref-type="ref"} Furthermore, longer survival was reported in a 2017 study of locally advanced NSCLC patients with m*EGFR* (vs. wild *EGFR*) treated with CCRT,[37](#tca12847-bib-0037){ref-type="ref"} although the prognostic significance of m*EGFR* on recurrence was debated in a review paper published in 2016.[38](#tca12847-bib-0038){ref-type="ref"} In the TKI group, our five‐year OS result was 26%, close to the 25% estimated in a recent systematic review (see Appendix [B](#tca12847-supitem-0001){ref-type="supplementary-material"}).[39](#tca12847-bib-0039){ref-type="ref"}

Obviously there were many limitations to our study. First, as a non‐randomized study, treatment decisions (CCRT or TKI) were made by the physician in charge and were not randomized; therefore, the treatment groups might be unbalanced in potential confounder(s), although we used conventional regression as well as the PS method in our analyses. However, possible unmeasured confounder(s), such as weight loss, tumor burden, or *EGFR* mutation subtypes were not available in our study. Second, our study sample was quite small, particularly in the CCRT group, and thus was not powered to investigate the difference in survival in TKI versus CCRT groups, especially with major confounders and imbalance in the numbers in both arms. Third, AJCC 8th edition cancer staging has been used since 2018, which is slightly different to AJCC 7E. However, most of the scenarios of AJCC 8E stage IIIb--IIIc are compatible with AJCC 7E stage IIIb (see Appendix [C](#tca12847-supitem-0001){ref-type="supplementary-material"}). Therefore, our results could be largely applied to AJCC 8E clinical stage IIIb--IIIc. Finally, other important endpoints, such as PFS or quality of life, were not investigated because of data limitations.

Given these limitations, our findings are not conclusive but we have provided a rationale to consider upfront TKI alone as a treatment alternative for locally advanced NSCLC with m*EGFR*, until the results of prospective clinical trials are available. However, when we searched <http://www.clinicaltrials.gov>/ using the keywords "condition/disease: lung cancer stage III & intervention/treatment: gefitinib (or erlotinib, afatinib, osimertinib)" on 24 July 2018 (66 trials: gefitinib \[*n* = 19\], erlotinib \[*n* = 38\], afatinib \[*n* = 4\], osimertinib \[*n* = 5\]), we did not find any current randomized studies comparing TKI versus CCRT for locally advanced NSCLC with m*EGFR*, although we did find the abovementioned randomized phase II trial comparing TKI plus radiotherapy versus CCRT, which reported improved PFS with TKI plus radiotherapy.[9](#tca12847-bib-0009){ref-type="ref"}

In this limited sample population‐based study from Taiwan, there was no statistically significant difference in survival outcomes of AJCC 7E clinical stage IIIb LA‐m*EGFR* patients treated with either EGFR‐TKIs or CCRT. Further prospective studies are required to clarify our findings.
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###### 
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